Placebo matching BI 3804379

Phase 1

Placebo matching BI 3804379 is one of 4 therapeutic programs targeting Metabolic Dysfunction-associated Steatohepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metabolic Dysfunction-Associated SteatohepatitisRecruiting

Metabolic Dysfunction-Associated SteatohepatitisPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Metabolic Dysfunction-Associated Steatohepatitis

#DrugCompanyPhaseTrials

Efimosfermin

BBoston Pharmaceuticals

Phase 2

1 2

ECC4703

EEccogene

Phase 2

1 3

ECC0509

EEccogene

Phase 2

1 4

Placebo matching BI 3804379

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Metabolic Dysfunction-Associated Steatohepatitis

NCT06575400

Clinical

Trials by Indication[1]

Metabolic Dysfunction-associated Steatohepatitis1 trial

A Phase 1, Randomised, Single-blind, Placebo-controlled Trial to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Subcutaneous Doses of BI 3804379 in Healthy Male and Female Participants and in Stable Patients With Advanced Fibrosis Due to MASH

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06575400·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo matching BI 3804379. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo matching BI 3804379. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Boehringer Ingelheim

Placebo matching BI 3804379

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Metabolic Dysfunction-associated Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News